EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages

Miriam Belmonte iD, Anna Albiero, Filip Callewaert, Julien Patris, Amanda Whittal iD

Vox Sanguinis · 2025

DOI: 10.1111/vox.70052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vox Sanguinis, 2025. Verfasst von Miriam Belmonte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dolon Ltd., London, UK. Hauptthemen laut MEDLINE: Plasma, COVID-19, Immunoglobulins, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: argenx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma‐derived medicinal products (PDMPs), particularly immunoglobulins (Igs), are essential treatments for numerous diseases, often serving as the primary therapeutic option and playing a critical role in patient care. The human origin of these products, however, can lead to supply constraints due to a lack of plasma collection, market dynamics, regulatory challenges and manufacturing complexities. Many nations lack plasma self‐sufficiency and often rely on the United States, which supplies approximately 70% of the world's plasma. This supply chain is vulnerable to disruptions, such as those caused by COVID‐19. Additionally, plasma processing timelines are lengthy—Ig manufacturing takes 7–12 months compared with 2–3 months for biologics. Despite the global Ig market's projected growth from $13.36 billion to $24.98 billion between 2023 and 2032, plasma shortages persist. The European Medicines Agency anticipated shortages to affect 14 European countries in 2024. These factors can have significant implications for patients, with growing demand likely leading to supply challenges and forcing countries to prioritize certain indications in the face of shortages. Policy interventions may be needed to ensure the sustainable use of these products in treating immune‐mediated disorders and related conditions. Exploring alternative treatments where possible could also mitigate the risk of shortages and maintain access to these life‐saving therapies. This review examines the sustainability of PDMPs, focusing on drivers and consequences of shortages, insufficient plasma collection, vulnerability of the plasma supply chain and impacts on patients. A scoping literature research was conducted in PubMed, supplemented by internal knowledge and targeted web searches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasmaCOVID-19ImmunoglobulinsBiological ProductsHumansSARS-CoV-2United StatesEurope

Stichwörter der Autor:innen

intravenous immunoglobulinsplasma supplyplasma‐derived medicinal productsshortagessustainability

Substanzen

ImmunoglobulinsBiological Products

Autor:innen und Institutionen

  • Dolon Ltd., London, UK.
  • argenx, Ghent, Belgium.

ORCID-Profile: Miriam Belmonte, Amanda Whittal

Förderung

  • argenx

Zitieren

APA

Belmonte, M., Albiero, A., Callewaert, F., Patris, J., & Whittal, A. (2025). Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages. Vox Sanguinis. https://doi.org/10.1111/vox.70052

Vancouver

Belmonte M, Albiero A, Callewaert F, Patris J, Whittal A. Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages. Vox Sanguinis. 2025. doi:10.1111/vox.70052

BibTeX
@article{Belmonte2025,
  author = {Belmonte, Miriam and Albiero, Anna and Callewaert, Filip and Patris, Julien and Whittal, Amanda},
  title = {Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages},
  journal = {Vox Sanguinis},
  year = {2025},
  doi = {10.1111/vox.70052}
}
Kostenlos starten →